Press Releases

Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. , March 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company focused on DNA-based

LAWRENCEVILLE, N.J. , March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.

Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years LAWRENCEVILLE, N.J. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) , a clinical-stage

LAWRENCEVILLE, N.J. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation

OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month Period LAWRENCEVILLE, N.J. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN ), a

Preclinical results d emonstrate safe and efficient immune response with v accine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J. , Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on

LAWRENCEVILLE, N.J. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purchase agreement with certain institutional

Celsion   Corporation ’s   GEN-1 IL-12 Program in Ad vanced Ovarian Cancer to be Featured   in Poster Presentation Chief Science Officer Dr. Khursheed Anwer   to Present and   Participate in Two Panel Discussions LAWRENCEVILLE, N.J. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:

Balance Sheet Supports Focus o n Immuno-Oncology and   Next-Generation Vaccine Initiative Conference Call Begins Today   at 11:00 a.m.   Eastern Time LAWRENCEVILLE, N.J. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company focused on

LAWRENCEVILLE, N.J. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.